Overview
Anthony Paronneau focuses his practice on a broad range of corporate and transactional matters, with a particular focus on the pharmaceutical, medical device, biotech, and healthcare sectors.
He has extensive experience representing life sciences companies, private equity funds, and venture capital firms in complex M&A and private equity transactions, including acquisitions, venture financings, joint ventures, and divestitures.
Anthony regularly advises emerging growth companies and VC investors on the structuring and negotiation of early- and late-stage funding rounds, and has acted on numerous high-profile cross-border and domestic transactions involving leading innovators in the healthtech and biotech spaces.
In addition, he counsels life sciences clients on strategic partnerships, collaborations, licensing agreements, and distribution arrangements, supporting their growth and commercialization strategies across all stages of development.
Results
- Advised a syndicate of Amolyt Pharma’s historical investors on its EUR130 million Series C financing.
- Advised TRiCares, a pioneer in the minimally invasive treatment of tricuspid regurgitation, on its €47 million financing round following the closing of its Series C financing round
- Advised Biocorp Production SA, a French company listed on Euronext Growth which specializes in the design, development and manufacturing of delivery systems and innovative medical devices, including Mallya, a Bluetooth enabled smart add-on device for pen injectors, on its proposed acquisition by Novo Nordisk A/S.
- Advised Sofinnova Partners on the EUR 15 million investment in Cure51, a techbio company seeking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients, led by Sofinnova with participation from Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog
- Advised Crédit Mutuel Innovation on the Series C financing of UroMems, an international company developing an innovative, implantable mechatronic technology to treat stress urinary incontinence (SUI).
- Advised Brightflow SAS, a privately held pioneer in the field of long-term percutaneous mechanical circulatory support to treat end-stage heart failure patients, on its Serie A fundraising.
Recognitions
- Chambers France, Band 3 in Pharma/Life Sciences: Corporate, 2025
- The Best Lawyers in France, Biotechnology & Life Sciences, 2025 & 2026
- Chambers Europe, France: Pharma/Life Sciences: Corporate, 2022-2024
- The Legal 500 EMEA, Leading Individual in France: Healthcare & Life Sciences, 2022 -2025
- IFLR1000, Corporate and M&A, 2022-2023
- Décideurs Juridiques, Capital Investments: Operational Risk, Excellent, 2020
- Décideurs Juridiques, Health, Pharma and Biotechnology: Digital Health, Forte Notoriété, 2019
- Décideurs Juridiques, Health, Pharma and Biotechnology: Regulatory, Excellent, 2019
- Décideurs Juridiques, Health, Pharma and Biotechnology: Joint Ventures and Corporate, Incontournable, 2019
- Décideurs Juridiques, Health, Pharma and Biotechnology: Capital Risk, Incontournable, 2019
